|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
This 30-page eBook is exactly what you have been looking for. Find out what is driving the lyophilization market and how working with a CDMO will save time and money and help you comply with increasing regulatory requirements.
|
|
 |
|
Thanks to our many GMP manufacturing sites located in North America, Europe and Asia we can provide the critical ingredients for your Biopharma manufacturing applications.
|
|
|
|
|
|
|
|
|
Adi Kaushal, Director and Technology Head, Bioavailability Enhancement at Lonza, discusses solubility and bioavailability challenges and Lonza’s approach.
|
|
|
Ram Mukunda, MS, and Evelyn Gutiérrez, and Claudia Grimaldi report on IGC-AD1, the first natural cannabinoid-based investigational drug to be tested in human FDA trials for the treatment of AD, which has shown promising results in treating agitation in Alzheimer’s patients.
|
|
|
Gregor Deutschle and Gabriele Maier examine key benefits, dynamics driving the adoption of RTU container platforms, and several important areas of continuing evolution in the RTU market.
|
|
|
Pieter Vercruysse says to overcome various challenges in 2024, pharma companies need to establish close partnerships with specialists focusing on PFS packaging.
|
|
|
Arthur A. Levin, PhD, highlights the first-ever successful targeted delivery of RNA to muscle in humans, a revolutionary advancement for the field of RNA therapeutics that may help transform the opportunities to advance research targeting many previously untreatable diseases in the years ahead.
|
|
|
|
|
|
|
|
|

Nanjing Well Pharmaceutical Group Co., Ltd., a high-tech enterprise from China specializing in R&D, manufacturing, and supplying pharmaceutical excipients and APIs. Our factory is located in Nanjing National New Materials Technology Park. We are currently one of the largest suppliers of pharmaceutical excipients for solid, semi-solid, and liquid preparations in China, with annual sales of more than 10,000 tons and sales of more than 40 million US dollars. We maintain long-term and stable cooperation with more than 1,000 pharmaceutical companies at home and abroad, such as Johnson & Johnson, GSK, Novartis, Bayer, and other multinational pharmaceutical companies. Click here for more.
|
|
|
|
|
|
 |
|
Drug-eluting implants offer a unique approach to overcoming challenges associated with traditional drug delivery methods. They can provide sustained, continuous release of a therapeutic at the desired site of action.
Download our latest white paper, jointly authored with MeltPrep, to …
|
|
 |
|
By: Mark Rauckhorst, Director Supply Chain and Project Management, Vetter Development Service USA. Inc.
Clinical trials are high-visibility milestones for investors, as this is often the first major step toward financial return on what has likely been years of investment …
|
|
 |
|
A key focus of the U.S. Food and Drug Administration’s evaluation of a medical device’s safety and effectiveness is reviewing its material makeup. If improperly tested – and impure materials are used – there is an elevated risk of contamination …
|
|
 |
|
Aseptic processing with the highest degree of sterility assurance, filling accuracy, and quality is critical for high-value, small-batch therapies. This white paper explores the specialized equipment, expertise, and services needed for efficient biologics fill/finish manufacturing.
CLICK HERE TO DOWNLOAD/VIEW THE …
|
|
|
|
|
Upcoming eNewsletter Features:
June 26 – Excipients
July 3 – Controlled Release
|
|
|
|
|
|
|
|